Business description: Abcam

Number of employees: 1,760
Sales by Activity: Abcam
| Fiscal Period: December | 2019 (GBP) | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) |
|---|---|---|---|---|
Sales of Antibodies and Related Products | 260M | 260M | 315M | 362M |
Geographical breakdown of sales: Abcam
| Fiscal Period: December | 2019 (GBP) | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) |
|---|---|---|---|---|
The Americas | - | 112M | 130M | 162M |
EMEA | - | 69.3M | 84.3M | 90.1M |
China | 39.9M | 39.5M | 58.2M | 62.9M |
Rest of Asia | - | 20M | 23.8M | 28.3M |
Japan | 16.9M | 18.8M | 18.7M | 17.9M |
United Kingdom (UK) | 13.6M | - | - | - |
Other Countries | 58.7M | - | - | - |
Germany | 15.2M | - | - | - |
United States (US) | 116M | - | - | - |
Executive Committee: Abcam
| Manager | Title | Age | Since |
|---|---|---|---|
Alan Hirzel
CEO | Chief Executive Officer | 58 | 09/09/2014 |
Markus Lusser
PSD | President | 58 | 18/03/2024 |
Michael Baldock
DFI | Director of Finance/CFO | 62 | 03/02/2020 |
Tommy J. Thomas
IRC | Investor Relations Contact | - | 27/06/2022 |
Emma Sceats
SAM | Sales & Marketing | - | - |
Composition of the Board of Directors: Abcam
| Director | Title | Age | Since |
|---|---|---|---|
Alan Hirzel
BRD | Director/Board Member | 58 | 01/01/2014 |
Mara Aspinall
BRD | Director/Board Member | 63 | 14/09/2015 |
Giles Kerr
BRD | Director/Board Member | 67 | 12/12/2018 |
Michael Baldock
BRD | Director/Board Member | 62 | 03/02/2020 |
Luba Greenwood
BRD | Director/Board Member | 47 | 12/09/2022 |
Markus Lusser
BRD | Director/Board Member | 58 | 29/07/2025 |
Company details: Abcam

Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.14% | +4.30% | +42.24% | -0.44% | 83.96B | ||
| -19.58% | +125.22% | +433.10% | +29.05% | 69.62B | ||
| +2.84% | +23.66% | -24.08% | -36.73% | 56.76B | ||
| +1.94% | +1.61% | -0.03% | +32.78% | 51.35B | ||
| +0.05% | -0.55% | +11.63% | +167.36% | 48.41B | ||
| -0.89% | +4.45% | +58.30% | -17.00% | 32.74B | ||
| +1.02% | +7.45% | +50.23% | +99.60% | 26.04B | ||
| +3.00% | +5.91% | +3.53% | +221.78% | 21.81B | ||
| -0.90% | +2.85% | +62.35% | +124.85% | 17.11B | ||
| Average | -1.43% | +24.26% | +70.81% | +69.03% | 45.31B | |
| Weighted average by Cap. | -2.65% | +34.72% | +91.35% | +45.85% |

















